GUO Yulian. Effect of furosemide combined with levosimendan on cardiac function and N-terminal B-type natriuretic peptide in patients with refractory heart failure[J]. Journal of Clinical Medicine in Practice, 2020, 24(18): 47-49. DOI: 10.7619/jcmp.202018013
Citation: GUO Yulian. Effect of furosemide combined with levosimendan on cardiac function and N-terminal B-type natriuretic peptide in patients with refractory heart failure[J]. Journal of Clinical Medicine in Practice, 2020, 24(18): 47-49. DOI: 10.7619/jcmp.202018013

Effect of furosemide combined with levosimendan on cardiac function and N-terminal B-type natriuretic peptide in patients with refractory heart failure

More Information
  • Received Date: June 22, 2020
  • Objective To investigate the effect of furosemide combined with levosimendan on cardiac function and N-terminal B-type natriuretic peptide(NT-proBNP)in patients with refractory heart failure. Methods A total of 80 patients with refractory heart failure were randomly divided into experimental group and control group, with 40 cases in each group. The control group was treated with furosemide, while the experimental group was treated with levosimendan combined with furosemide. Cardiac function index, inflammatory factor and clinical efficacy were compared between the two groups. Results After treatment, NT-proBNP, serum hypersensitive C-reactive protein(hS-CRP)and the levels of interleukin-6(IL-6)in the experimental group were significantly lower than those in the control group(P<0.05); left ventricular ejection fraction(LVEF)and stroke volume(SV)were significantly higher than those in the control group(P<0.05). The total effective rate of the experimental group was 80.00%, which was significantly higher than 57.50% of the control group(P<0.05). Conclusion The treatment of refractory heart failure with furosemide combined with levosimendan can significantly improve the heart function, and reduce the inflammatory response in patients with refractory heart failure.
  • 张亮, 李海林. 左西孟旦对顽固性心力衰竭患者心功能的影响[J]. 中国中西医结合急救杂志, 2019, 26(3): 307-309.
    朱宏旭, 宋丽萍, 耿学峰. 左西孟旦联合多巴胺对顽固性心力衰竭患者心功能及心肌损伤的影响[J]. 临床和实验医学杂志, 2019, 18(13): 1404-1407.
    刘杲, 伊争伟, 张鹏博. 左西孟旦联合托伐普坦对顽固性心力衰竭患者氧化应激心肌损伤及心功能的影响[J]. 安徽医学, 2019, 40(6): 683-685.
    周红瑜, 厉旭光, 颜碧清. 左西孟旦对急性心力衰竭患者心功能和血流动力学及炎性因子的影响[J]. 中国医药, 2018, 13(11): 1605-1608.
    林施峰, 李世阁, 林基表, 等. 左西孟旦对扩张型心肌病慢性心力衰竭患者心功能的影响及疗效观察[J]. 安徽医学, 2018, 39(11): 1339-1343.
    汪雁博, 郝国贞, 姜云发, 等. 左西孟旦对急性失代偿性心力衰竭患者右心功能的影响研究[J]. 中国全科医学, 2019, 22(27): 3328-3332.
    汪月奔, 虞意华, 龚仕金, 等. 左西孟旦治疗32例高龄重症心力衰竭患者的疗效与安全性[J]. 中华内科杂志, 2020, 59(6): 433-438.
    周志祥, 黄元飞. 左西孟旦联合美托洛尔对老年慢性心力衰竭患者心功能、N端脑钠肽前体和心室重构的影响[J]. 药物评价研究, 2019, 42(6): 1156-1159.
    康丽惠, 牛永红, 康林, 等. 左西孟旦联合血液超滤治疗顽固性心力衰竭患者的疗效观察[J]. 中国循证心血管医学杂志, 2019, 11(8): 954-956.
    耿红亮, 白广海, 王恒亮. 左西孟旦联合利尿剂治疗顽固性心衰的疗效及对NT-proBNP、hs-CRP、IL-6水平的影响[J]. 慢性病学杂志, 2017, 18(11): 1286-1288.
    李筱璇, 欧会清, 徐燕娜, 等. 左西孟旦和米力农治疗难治性心力衰竭的疗效比较及对血清NT-proBNP、ET-1水平的影响[J]. 现代生物医学进展, 2018, 18(3): 481-484.
    陈元椿. 左西孟旦、米力农对AHF患者的疗效及对血清NT-proBNP、NE和ET-1水平的影响分析[J]. 心血管康复医学杂志, 2018, 27(3): 313-317.
    冯茜, 苏晓娟, 刘小毅, 等. 左西孟旦联合螺内酯对慢性心力衰竭患者血清炎症因子水平及心室重构的影响研究[J]. 现代生物医学进展, 2019, 19(10): 1916-1919

    , 1957.
    刘艳娜, 李晓东, 张琼, 等. 左西孟旦联合呋塞米治疗顽固性心力衰竭的疗效分析[J]. 现代生物医学进展, 2017, 17(6): 1149-1151

    , 1171.
    吴林栩, 王卿语, 叶张章, 等. 常规治疗加用左西孟旦治疗慢性进展性心力衰竭的疗效[J]. 心脏杂志, 2018, 30(6): 713-715.

Catalog

    Article views (332) PDF downloads (15) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return